Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 19/20 | 0.62 |
| ▸ | PIK3CA | P42336 | 16/20 | 0.62 |
| ▸ | MTOR | P42345 | 15/20 | 0.62 |
| ▸ | ATR | Q13535 | 3/20 | 0.62 |
| ▸ | PRKDC | P78527 | 2/20 | 0.62 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.62 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.62 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30013029 | 0.91 | ATM (0.59) | ATMPIK3CAMTORATRPRKDC | |
| SCHEMBL30011064 | 0.89 | ATM (0.65) | ATMPIK3CAMTORATRPRKDC | |
| SCHEMBL30013129 | 0.86 | ATM (0.47) | ATMPIK3CAMTORATRPRKDC | |
| SCHEMBL30012141 | 0.85 | ATM (0.58) | ATMPIK3CAMTORATRPRKDC | |
| SCHEMBL22891694 | 0.84 | ATM (0.62) | ATMPIK3CAMTORATRPRKDC | |
| SCHEMBL30011731 | 0.84 | ATM (0.62) | ATMPIK3CAMTORATRPRKDC | |
| SCHEMBL30359531 | 0.82 | ATM (0.61) | ATMPIK3CAMTORATRPRKDC | |
| SCHEMBL21541811 | 0.82 | ATM (0.61) | ATMPIK3CAMTORATRPRKDC | |
| SCHEMBL30012580 | 0.81 | ATM (0.62) | ATMPIK3CAMTORATRPRKDC | |
| SCHEMBL30012584 | 0.81 | ATM (0.54) | ATMPIK3CAMTORATRPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220259211-A1 | SUBSTITUTED PYRAZOLOQUINAZOLINONE COMPOUNDS AND APPLICATION THEREOF | Impact Therapeutics (Shanghai), Inc (CN) | 2022-08-18 | — | — | US | claimed |
| US-20220259211-A1 | SUBSTITUTED PYRAZOLOQUINAZOLINONE COMPOUNDS AND APPLICATION THEREOF | Impact Therapeutics (Shanghai), Inc (CN) | 2022-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220259211-A1 | SUBSTITUTED PYRAZOLOQUINAZOLINONE COMPOUNDS AND APPLICATION THEREOF | CHEK1, CHEK2, ATM | ATM 3/4885PIK3CA 381/4885MTOR 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.